- $64.37m
- -$50.66m
- $63.26m
Brief: Fortress Biotech, Cyprium Therapeutics Announce $4.1 Mln Grant From NINDS
Brief: Avenue Therapeutics Inc - REACHES FINAL AGREEMENT WITH THE U.S. FDA FOR THE PHASE 3 SAFETY STUDY
Brief: Journey Medical Corporation Secures Credit Facility With SWK Holdings For Up To $20 Million
Brief: Fortress Biotech Announces Pricing Of $11 Million Registered Direct Offering
Brief: Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
Brief: Checkpoint Therapeutics Strengthens Intellectual Property Protection For Cosibelimab With New U.S. Patent Issuance
U.S. STOCKS ON THE MOVE-Primerica, Canopy Growth, Applied Materials
U.S. STOCKS ON THE MOVE-Hologic, Blink Charging, Adobe
U.S. STOCKS ON THE MOVE-Doximity , Hologic, Blink Charging
Fortress Biotech shares plunge after highly dilutive offering
Brief: Fortress Biotech Announces Pricing of $10 Mln Public Offering
Brief: Fortress Biotech Announces Launch Of Proposed Public Offering
Brief: Avenue Therapeutics Announces Pricing Of $5.0 Million Public Offering
Brief: Fortress Biotech Inc says On Oct 24 Was Notified By Nasdaq That Co Has Evidenced Compliance With $1.00 Bid Price Requirement For Continued Listing
Brief: Mustang Bio Announces FDA Acceptance Of IND Application For MB-109
Brief: Journey Medical Announces Data from Bioavailability Study of DFD-29 vs Solodyn
Brief: Checkpoint Therapeutics Announces Publication Of Cosibelimab Pivotal Trial Results
Brief: Fortress Biotech Subsidiary Helocyte Announces Option Agreement With City Of Hope For Exclusive Worldwide Rights To Use A Novel Bispecific CMV/HIV CAR T Cell Therapy
Brief: Fortress Biotech Announces Reverse Stock Split